[The killing effect of cytotoxic T lymphocytes on esophageal adenocarcinoma cells mediated by gp96-peptide complexes].
OBJECTIVE
To study the immunotherapeutic effect on the esophageal adenocarcinoma mediated by gp96-peptide complexes isolated from the same kind of tumor.


METHODS
gp96-peptide complexes were purified from nude mice tumors burdened by subcutaneous injection of human esophageal adenocarcinoma cell line SEG-1. gp96-peptide complexes were carried by the dendritic cells(DC) induced from human peripheral blood mononuclear cells to prepare gp96-DC vaccine. The proliferation of lymphocytes was tested with trypan-blue stain. The quantity of interferon-gamma(IFN-gamma) released from cytotoxic T lymphocytes (CTL) was detected with ELISA method. The killing effect of CTL on target cell SEG-1 was measured with MTT.


RESULTS
We obtained 120 microg gp96 from 55 g tumor tissue. DC, gp96, and gp96-DC all could elicit the proliferation of lymphocytes and make them becoming into CTL which released IFN-gamma and showed different degrees of killing effect on target cell SEG-1. gp96-DC has the strongest eliciting effect among them. At the ratio of E(effect) to T(target) as 40:1,the killing rate was 68%. No significant difference between the effects of CTL induced by DC alone and of lymphocytes without specific antigen on SEG-1 and K562 cells.


CONCLUSIONS
The gp96-peptide complexes from tumors can improve the effect of eliciting lymphocyte proliferation of DC and make the lymphocyte becoming into CTL more effectively. These CTLs show prominent killing effect on the target tumor cells.
Ma
Li-ping
LP
Central Laboratory, Peking University People's Hospital, Beijing 100044, China. lipingma2000@yahoo.com.cn
Pan
Xiu-ying
XY
Li
Na
N
Liu
Yu-jing
YJ
Chen
Xiao-xin
XX
D000230:Adenocarcinoma / Q000276:immunology* / Q000473:pathology; D000818:Animals; D000951:Antigens, Neoplasm / Q000276:immunology*; D019496:Cancer Vaccines / Q000276:immunology; D045744:Cell Line, Tumor; D002470:Cell Survival / Q000276:immunology; D003713:Dendritic Cells / Q000276:immunology; D004938:Esophageal Neoplasms / Q000276:immunology* / Q000473:pathology; D005260:Female; D006801:Humans; D008297:Male; D051379:Mice; D008819:Mice, Nude; D009368:Neoplasm Transplantation; D013602:T-Lymphocytes, Cytotoxic / Q000276:immunology*; D014183:Transplantation, Heterologous; D014614:Vaccines, Synthetic / Q000276:immunology
D000951:Antigens, Neoplasm; D019496:Cancer Vaccines; D014614:Vaccines, Synthetic; C052646:sarcoma glycoprotein gp96 rejection antigens